her-2 car-t cells
Cell therapyexperimental
Clinical trial activity
9 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2013 (NCT01935843)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1/Phase 2
- Choroid Plexus Neoplasms · Phase 1
- Colorectal Neoplasms · Phase 1/Phase 2
- Drug-Related Side Effects and Adverse Reactions · Phase 1/Phase 2
- Ependymoma · Phase 1
- Esophageal Neoplasms · Phase 1
- Genes, erbB-2 · Phase 1/Phase 2
- Glioma · Phase 1/Phase 2
- Lung Neoplasms · Phase 1/Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 2
- Medulloblastoma · Phase 1
- Neoplasms · Phase 1/Phase 2
- Neoplasms, Germ Cell and Embryonal · Phase 1
- Neuroectodermal Tumors, Primitive · Phase 1
- Ovarian Neoplasms · Phase 1/Phase 2
- Pancreatic Neoplasms · Phase 1/Phase 2
- Pinealoma · Phase 1
- Rhabdoid Tumor · Phase 1
- Salivary Gland Neoplasms · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 1
- Stomach Neoplasms · Phase 1/Phase 2
- Urinary Bladder Neoplasms · Phase 1
Mechanism of action
- Receptor protein-tyrosine kinase erbB-2Immunity, passive
ERBB2 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- anti-her2 car-t
- cart-her-2
- her-2-targeting car t cells infusion
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06658951 | N/A | Nov 30, 2024 | UTC Therapeutics Inc., Zhengzhou University |
| NCT05757219 | Phase 2 | May 19, 2023 | Incyte, University of South Florida |
| NCT05745454 | N/A | Feb 28, 2023 | People's Liberation Army of China |
| NCT04650451 | Phase 1 | Dec 7, 2020 | Bellicum Pharmaceuticals |
| NCT03740256 | Phase 1 | Jan 1, 2019 | Baylor University, Methodist Cancer Center, Houston, Texas |
| NCT03500991 | Phase 1 | Jul 26, 2018 | University of Washington |
| NCT02713984 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2016 | People's Liberation Army of China, Southwest Hospital, China |
| NCT02547961 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2015 | Jinan University |
| NCT01935843 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2013 | People's Liberation Army of China |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| People's Liberation Army of China | Government | 3 | 2 | 2 | 2013 |
| Baylor University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Bellicum Pharmaceuticals | For profit | 1 | 1 | 1 | 2020 |
| Incyte | For profit | 1 | 0 | 1 | 2023 |
| Jinan University | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Methodist Cancer Center, Houston, Texas | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Southwest Hospital, China | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of South Florida | Academic/Hospital | 1 | 1 | 1 | 2023 |
| University of Washington | Academic/Hospital | 1 | 1 | 1 | 2018 |
| UTC Therapeutics Inc. | For profit | 1 | 1 | 1 | 2024 |
| Zhengzhou University | Academic/Hospital | 1 | 0 | 1 | 2024 |
11 organizations
Page 1 / 1